Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
|
|
United Press International - November 11, 2008
PITTSBURGH, Nov. 11 (UPI) -- U.S. and British scientists say they've created T cells able to recognize human immunodeficiency virus strains that have evaded the body's immune system.
Researchers at the University of Pennsylvania School of Medicine and colleagues in the United Kingdom said their achievement has important implications for developing new treatments for HIV.
Natural T cells recognize their targets through weak molecular interactions mediated by the T cell receptor, the researchers said. The scientists were able to isolate a group of T cell receptor encoding genes that bind to HIV-1 about 450 times more strongly.
"Not only could T cells engineered to express the strongly binding T cell receptor see HIV strains that had escaped detection by natural T cells, but the engineered T cells responded in a much more vigorous fashion so that far fewer T cells were required to control infection," said Penn Associate Professor James Riley.
"In the face of our engineered assassin cells, the virus will either die or be forced to change its disguises again, weakening itself along the way," added Professor Andy Sewell of Cardiff University, co-senior author of the study. "We'd prefer the first option, but I suspect we'll see the latter."
The study that included scientists from Britain's Wellcome Trust, Oxford University and Adaptimmune Ltd., a British company that owns the rights to the technology, appears online in the journal Nature Medicine.
On the Net: Nature Medicine and Nature
References:
1. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med. 2008 Nov 9. [Epub ahead of print]
2. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2008 Nov 9[Epub ahead of print]
Copyright © 2008 - United Press International. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through United Press International, Permissions Desk, 1510 H St. N.W. Washington DC 2005. Main Phone Switchboard: 202-898-8000 FAX: 202-898-8057 or 202-898-8147 Email: info@upi.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .